Related Experiment Video
Updated: Aug 23, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
[Cyclooxygenase 2 inhibitors and colorectal cancer]
Marianne Bernardeau-Mozer1, Stanislas Chaussade
1Service d'Hépato-gastroentérologie Pavilion Achard 9e, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75014 Paris.
Abstract:
Cyclooxygenase-2 (Cox2) is an inductible isoenzyme of cyclooxygenase undetectable in normal colonic mucosa and overexpressed in 80% colonic tumor. Several works in vitro and in vivo showed that Cox2 plays a key role in the multistep process of colorectal tumorigenesis such apoptosis inhibition of cellular proliferation and angiogenesis induction. So that Cox2 represent a potential molecular target in colorectal management and specific Cox2 inhibitors may be useful as chemopreventive as well as therapeutic agent in humans. In animals study Cox2 inhibitors was shown to be effective and in humans Cox2 inhibitors are approved by the Food and Drug Administration as an adjunct to endoscopic surveillance and surgery in patients with Familial Adenomatous Polyposis (FAP). The purpose of this article is to review the relationship between Cox2/Cox2 inhibitors and differents signaling pathways of colorectal carcinogenesis and to precise their possible molecular mechanisms of action. This work although review clinicals data of their efficacy as chemopreventive agent as well as therapeutic in the differents group at risk for colorectal cancer.
Insights
Cyclooxygenase-2 (Cox2) is overexpressed in most colorectal tumors and drives cancer growth. Cox2 inhibitors show promise for preventing and treating colorectal cancer, especially in high-risk individuals.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Context:
- Cyclooxygenase-2 (Cox2) is an inducible enzyme overexpressed in 80% of colorectal tumors.
- Cox2 plays a critical role in colorectal tumorigenesis by inhibiting apoptosis, promoting cellular proliferation, and inducing angiogenesis.
Purpose:
- To review the relationship between Cox2/Cox2 inhibitors and colorectal carcinogenesis signaling pathways.
- To clarify the molecular mechanisms of action for Cox2 inhibitors in colorectal cancer.
Summary:
- Cox2 is a key molecular target in colorectal cancer management.
- Cox2 inhibitors have demonstrated efficacy in animal studies and are approved for specific patient groups in humans.
- This review examines clinical data on the chemopreventive and therapeutic efficacy of Cox2 inhibitors across various risk groups for colorectal cancer.
Impact:
- Cox2 inhibitors represent a potential therapeutic strategy for colorectal cancer.
- Understanding Cox2 signaling pathways can lead to improved chemopreventive and therapeutic interventions.
- This review provides insights into the clinical utility of Cox2 inhibitors for colorectal cancer management.
More Related Videos
06:24Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
Published on: October 13, 2023
10:01Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Drugs for Treatment of Ulcerative Colitis in IBD
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...